公开(公告)号：US20240180919A1

公开(公告)日：2024-06-06

申请号：US18496074

申请日：2023-10-27

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61K9/00 ,  A61P35/00

CPC classification number: A61K31/5377 ,  A61K9/0053 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20220288085A1

公开(公告)日：2022-09-15

申请号：US16306182

申请日：2017-06-01

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61P35/04 ,  A61K9/00

Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

公开(公告)号：US20230075198A1

公开(公告)日：2023-03-09

申请号：US17268151

申请日：2019-08-14

Applicant: EPIZYME, INC.

Inventor： John LAMPE ,  John CAMPBELL ,  Kenneth DUNCAN ,  Megan Alene Cloonan FOLEY ,  Darren Martin HARVEY ,  Michael John MUNCHHOF ,  Michael THOMENIUS ,  Lawrence Alan REITER

IPC: C07D403/12 ,  C07D487/04 ,  C07D401/12 ,  C07D471/10 ,  C07D471/04 ,  C07D403/14 ,  C07D413/12 ,  C07D209/08 ,  C07D413/14 ,  C07D487/08 ,  C07D471/08 ,  C07D491/107 ,  C07D405/12 ,  C07D417/12 ,  C07D409/12 ,  C07D498/10 ,  C07D487/10 ,  C07D513/10 ,  C07D401/14 ,  C07D491/08 ,  C07D417/14 ,  C07D498/08 ,  A61P35/00

Abstract: The present disclosure provides substituted indole compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1e, G1, G2, Q1, Q2, Q3, and (II) are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.

公开(公告)号：US20220105098A1

公开(公告)日：2022-04-07

申请号：US17474202

申请日：2021-09-14

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61K9/00 ,  A61P35/00 ,  A61K45/06

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

公开(公告)号：US20240139203A1

公开(公告)日：2024-05-02

申请号：US18462229

申请日：2023-09-06

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61K9/00 ,  A61P35/04

CPC classification number: A61K31/5377 ,  A61K9/0019 ,  A61K9/0053 ,  A61P35/04

Abstract: The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

公开(公告)号：US20230049113A1

公开(公告)日：2023-02-16

申请号：US17294959

申请日：2019-11-26

Applicant: EPIZYME, INC.

Inventor： Michael THOMENIUS ,  Katherine Louise COSMOPOULOS ,  Jennifer Anne TOTMAN

IPC: A61K31/404 ,  A61P35/00 ,  A61K31/4985 ,  A61K31/496 ,  A61K31/438 ,  A61K31/541 ,  A61K31/4439 ,  A61K31/437 ,  A61K31/5377 ,  A61K31/407 ,  A61K31/422 ,  A61K31/519 ,  A61K31/4709 ,  A61K31/551 ,  A61K31/454 ,  A61K31/55 ,  A61K31/439 ,  A61K31/506 ,  A61K31/4245 ,  A61K31/433 ,  A61K31/4725 ,  A61K31/5386 ,  A61K31/427 ,  A61K31/415 ,  A61K31/4995 ,  A61K31/4196 ,  A61K31/4155 ,  A61K31/517 ,  A61K31/4178 ,  A61K31/537 ,  A61K31/499

Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancers that overexpress the histone methyltransferase WHSC1, e.g., t(4; 14) multiple myeloma, by administering to a subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.

公开(公告)号：US20210002645A1

公开(公告)日：2021-01-07

申请号：US16639424

申请日：2018-08-14

Applicant: EPIZYME, INC.

Inventor： Alexandra Rose Grassian ,  Michael THOMENIUS ,  Jennifer Anne TOTMAN

IPC: C12N15/113 ,  C07K16/40 ,  C12N9/22 ,  C12N15/11 ,  A61K38/46 ,  A61K31/7088 ,  A61K31/7076 ,  A61K39/395

Abstract: The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.

公开(公告)号：US20190328743A1

公开(公告)日：2019-10-31

申请号：US16310597

申请日：2017-06-16

Applicant: Epizyme, Inc.

Inventor： Scott RIBICH ,  Michael THOMENIUS

IPC: A61K31/5377 ,  A61P35/00 ,  A61K9/00

Abstract: The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.